| |
After Myocardial Infarction – thromboembolic events such as stroke or systemic embolization is very common. Such indications are well treated with Warfarin which is a coumarin anticoagulant.
WARFEN is our brand of Warfarin. WARFEN acts by inhibiting Vitamin K dependant coagulation factors.
WARFEN is used for the prophylaxis and or treatment of the thromboembolic complications associated with atrial fibrillation and or cardiac valve replacement. WARFEN is also used for the treatment of Venous Thrombo embolism and pulmonary embolism.
WARFEN tablets are used to reduce the risk of death and recurrent myocardial infarction.
GLIMSEN™ 1
GLIMSEN is indicated as an adjunct to proper dietary management, exercise and weight reduction to lower blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
- GLIMSEN has low risk of hypoglycemic.
- GLIMSEN has potent blood -glucose lowering effect with less stimulation of insulin secretion, possibly due to more pronounced extra pancreatic effects.
- GLIMSEN has lower dosage, rapid onset and long duration of action
- GLIMSEN can be used in combination with Metformin, the thiazoliinodiones, alphaglucosidase inhibitors and insulin.
- GLIMSEN can be used in older patients and those with renal compromise.
GLIMSEN - dosage - initially 1-2 mg daily administered with breakfast or the first main meal and maintenance dose 4 mg daily and maximum daily dose 8 mg.
|
